These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 14613601)
1. An opportunity for medication risk reduction, healthcare provider collaboration, and improved patient care: a retrospective analysis of osteoporosis management. Bernett GB; Feldman S; Martin H; Smith BC; Raineri BD J Am Med Dir Assoc; 2003; 4(6):329-36. PubMed ID: 14613601 [TBL] [Abstract][Full Text] [Related]
2. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644 [TBL] [Abstract][Full Text] [Related]
3. [Quality of life of patients suffering from osteoporosis treated with alendronate and salmon calcitonin]. Sapuła RA; Ostrowski T; Bojar I Wiad Lek; 2002; 55 Suppl 1():444-7. PubMed ID: 15002282 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426 [TBL] [Abstract][Full Text] [Related]
6. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Jamal SA; Bauer DC; Ensrud KE; Cauley JA; Hochberg M; Ishani A; Cummings SR J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862 [TBL] [Abstract][Full Text] [Related]
7. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264 [TBL] [Abstract][Full Text] [Related]
9. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133 [TBL] [Abstract][Full Text] [Related]
10. Compliance with osteoporosis treatment guidelines in postmenopausal women. Mountjoy CR; Shrader SP; Ragucci KR Ann Pharmacother; 2009 Feb; 43(2):242-50. PubMed ID: 19196838 [TBL] [Abstract][Full Text] [Related]
11. Compliance of osteoporotic patients with different treatment regimens. Segal E; Tamir A; Ish-Shalom S Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753 [TBL] [Abstract][Full Text] [Related]
12. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Dursun N; Dursun E; Yalçin S Int J Clin Pract; 2001 Oct; 55(8):505-9. PubMed ID: 11695068 [TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
14. The clinical tolerability profile of alendronate. Watts N; Freedholm D; Daifotis A Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment. Briesacher B; Limcangco R; Simoni-Wastila L; Doshi J; Gurwitz J J Am Geriatr Soc; 2005 Jun; 53(6):991-6. PubMed ID: 15935022 [TBL] [Abstract][Full Text] [Related]
16. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. Martens MG J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513 [TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors. Compliance with a mandated step-up program. Mamdani MM; Tu K; Jaakkimainen L; Bica A; Hux J Can Fam Physician; 2001 Mar; 47():531-5. PubMed ID: 11281086 [TBL] [Abstract][Full Text] [Related]
18. Digoxin prescribing for heart failure in elderly residents of long-term care facilities. Misiaszek B; Heckman GA; Merali F; Turpie ID; Patterson CJ; Flett N; McKelvie RS Can J Cardiol; 2005 Mar; 21(3):281-6. PubMed ID: 15776118 [TBL] [Abstract][Full Text] [Related]
19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
20. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]